Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01250145 · ClinicalTrials.gov registry record · Phase 1
A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 251
- Enrollment target
NCT01250145 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 251 participants.
The verdict
NCT01250145, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 251 participants
- Enrollment target
Study Summary
This study is a Phase 1, multi-center, 2-part, subject- and investigator-blind, randomized, placebo-controlled, multiple dose study of transdermal teriparatide (80-µg dose) in healthy postmenopausal women. Part A will examine the cumulative irritation and adherence of the transdermal patch, and Part B will examine skin sensitization and adherence. Two separate groups of subjects will be enrolled for Part A and Part B of the study. All screening procedures will take place up to 28 days prior to enrollment.
Interventions
- DRUG Placebo
- DRUG LY333334
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01250145
The ClinicalTrials.gov registry entry for NCT01250145 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 251 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01250145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01250145 about?
NCT01250145 is a clinical study titled "A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women". This study is a Phase 1, multi-center, 2-part, subject- and investigator-blind, randomized, placebo-controlled, multiple dose study of transdermal teriparatide (80-µg dose) in healthy postmenopausal women. Part A will examine the cumulative irritation and adherence of the transdermal patch, and Part...
What is the current status of trial NCT01250145?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 251 participants. The study started on 2010-11. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01250145?
The interventions under investigation include: Placebo (DRUG), LY333334 (DRUG).
Who is sponsoring clinical trial NCT01250145?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.